BFH772 (VEGFR2 inhibitor): Technical Use and Workflow Guidance

What This Product Solves

BFH772 is a small-molecule inhibitor specifically designed to target the VEGFR2 kinase, a central mediator of angiogenesis in physiological and pathological contexts. By selectively inhibiting VEGFR2, BFH772 allows researchers to dissect VEGFR2-mediated signaling pathways with minimal off-target effects, which is critical in tumor angiogenesis models and studies of vascular biology. Its high affinity (IC50 of 3 nM) and substantial selectivity over related kinases make it a robust tool for identifying the roles of VEGFR2 in neovascularization and tumor growth. This compound addresses the need for precise modulation of VEGFR2-driven processes while minimizing interference with related receptors and kinases. For detailed product information, including purity and solubility data, see the BFH772 (VEGFR2 inhibitor) page.

Protocol Parameters

• Compound Solubility | ≥53.4 mg/mL in DMSO | Applies to in vitro and in vivo assay preparations requiring high-concentration stock solutions | Ensures adequate solubilization for accurate dosing; do not attempt dissolution in water due to insolubility | product dossier
• Working Concentration | User-defined, typically low nanomolar range | Suitable for cell-based or biochemical VEGFR2 inhibition assays | Starting at low nanomolar concentrations leverages the compound's reported IC50 (3 nM); titration recommended for specific model systems | workflow recommendation
• Storage Condition | -20°C (dry, protected from light) | Applies to both the solid compound and short-term DMSO/ethanol solutions | Maintains compound stability; avoid repeated freeze-thaw cycles and long-term solution storage | product dossier
• Vehicle Compatibility | DMSO and ethanol | Required for stock solution preparation and dosing | Use only compatible organic solvents as per solubility profile; do not use water-based vehicles | product dossier
• Purity | >96% | Ensures reliability in sensitive assays | High-purity reduces confounding from contaminants in kinase inhibition studies | product dossier

Workflow Setup and QC Checklist

To achieve reproducible results with BFH772 as a VEGFR2 signaling pathway inhibitor, follow these workflow recommendations:

• Stock Preparation: Dissolve BFH772 powder in DMSO or ethanol to the desired concentration, ensuring full dissolution by gentle vortexing or sonication. Due to its insolubility in water, do not attempt aqueous dissolution. Prepare aliquots to avoid repeated freeze-thaw cycles.
• Storage and Stability: Store the solid compound at -20°C in a desiccated environment, protected from light. Short-term storage (<1 week) of solutions at -20°C is acceptable, but discard solutions if precipitates form or after multiple freeze-thaw events.
• Vehicle Controls: Always include matched DMSO or ethanol vehicle controls in experimental assays to account for potential solvent effects on cells or tissues.
• QC Documentation: Confirm batch-specific purity (>96%) and identity using the supplied Certificates of Analysis and Safety Data Sheets. Document solution preparation dates and storage conditions in laboratory records.
• Assay Design: Begin with low nanomolar concentrations (e.g., 1–100 nM) in cell-based or biochemical assays, titrating as needed to determine optimal inhibition of VEGFR2 kinase activity. Carefully monitor for cytotoxicity at higher concentrations.
• Replicates and Reproducibility: Run all experiments in technical and biological replicates to confirm the reproducibility of anti-angiogenic effects.

For additional workflow discussions and protocol considerations, see the internal article "BFH772 (VEGFR2 inhibitor): Practical Use and Protocol Guidance", which highlights the importance of selectivity and solubility in experimental design.

Common Failure Modes and Fixes

• Incomplete Dissolution: If BFH772 does not fully dissolve in DMSO or ethanol at the desired concentration, gently heat (below 37°C) or sonicate, but do not exceed solvent compatibility limits. If undissolved material persists, reduce concentration or verify compound identity and purity.
• Precipitation in Assays: Upon dilution into culture media or buffer, precipitation may occur due to poor aqueous solubility. To minimize, keep final DMSO/ethanol concentration below 0.1–0.2% (v/v) in assays and add compound stocks to media slowly with thorough mixing.
• Reduced Inhibitory Effect: If expected inhibition of VEGFR2 signaling is not observed, verify compound freshness, solution clarity, and adherence to recommended storage. Confirm vehicle control results to rule out solvent-related effects.
• Batch Variability: Always check the Certificate of Analysis for each batch and document lot numbers to track potential performance differences.

For troubleshooting and further workflow strategies, refer to "BFH772 (VEGFR2 inhibitor): Technical Guidance for Angiogenesis Research", which discusses optimizing protocols for selective VEGFR2 inhibition.

Scope and Limitations

• Selective Use Only: BFH772 is intended for studies requiring highly selective VEGFR2 inhibition. It is unsuitable for broad-spectrum kinase inhibition or for workflows needing activity against FLK-1, FLT-1, FLT-4, B-RAF, RET, or TIE-2 due to its reduced potency against these targets.
• Solubility Constraints: This compound is insoluble in water and should not be used in protocols demanding aqueous stock solutions or delivery. Use only DMSO or ethanol as solvents, and carefully control final solvent concentrations in biological systems.
• Stability Considerations: Long-term storage of BFH772 in solution is not recommended. Prepare fresh aliquots as needed and store under specified conditions to prevent degradation.
• In vivo Application: Oral administration of BFH772 has demonstrated anti-angiogenic effects in animal tumor models, but formulation and dosing protocols must account for its solubility and stability profile as specified in the product documentation.
• Regulatory and Clinical Use: While BFH772 has advanced into clinical studies for rosacea, all research applications must adhere to local regulations and institutional guidelines. It is not approved for diagnostic or therapeutic use outside controlled studies.

Conclusion

BFH772 is a highly selective VEGFR2 kinase inhibitor suitable for angiogenesis and tumor research workflows that require precise pathway modulation. Its selectivity, solubility in organic solvents, and stability profile dictate strict adherence to protocol parameters for reliable outcomes. For full product specifications and supporting quality documentation, consult the BFH772 (VEGFR2 inhibitor) page at APExBIO. This compound is not suitable for workflows needing water solubility or broad kinase targeting, and best practices include rigorous control of solvent use, storage, and QC documentation. For further technical guidance, the referenced internal articles provide additional practical workflow recommendations specific to BFH772.